EDGAR·FLOW

Inmune Bio Inc. — Form S-1

Filed November 20, 2026 · analyzed by the Registration Agent
S-1 — Neutral significance 28/100
What the filing says
On October 27, 2026, Inmune Bio completed a registered direct offering of 3,000,000 common shares at $1.50/share ($4.5M gross proceeds) and concurrent private placement of warrants to Armistice Capital Master Fund Ltd. to purchase 3,000,000 additional shares at $1.65/share. This Form S-1 registers resale of the warrant shares; company retains potential to receive ~$4.95M if warrants are exercised for cash. No proceeds flow to company from resale itself, only from potential future warrant exercise.
Why this rating

Combined offering (~$9.45M potential total) is ~19% of $51M market cap—meaningful capital raise. However, this is routine follow-on financing for biotech pre-launch. No new clinical/commercial risk; resale registration is administrative requirement.

Extracted items
View original filing on SEC.gov ↗ INMB · stock on Yahoo Finance ↗

See more from November 20, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.